58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study
医学
实体瘤
癌症研究
肿瘤科
内科学
癌症
作者
Antoine Hollebecque,Efrat Dotan,Chih‐Yi Liao,Desamparados Roda,Elisa Fontana,Hani Babiker,R.D. Kim,Do‐Youn Oh,François Ghiringhelli,Irene Moreno,J. Liu,Vivek Subbiah,Andreas Varkaris,Mitesh J. Borad,P.A. Cassier,Alicia Deary,Florence Ramirez,Fabien Ricard,Kuang‐Yu Jen,Alison M. Schram